Despite initial volume curbs, Revlimid to be a meaningful opportunity; FY21-23e EPS up 1-3%; TP raised to Rs 5,400
from The Financial Express https://ift.tt/3iSOCmK
Monday, 21 September 2020
Dr Reddy’s Laboratories Rating’ buy’; patent deal dispels launch uncertainties
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment